GenScript Launches GMP-like mRNA Solution to address phase-appropriate drug development needs Sponsored By GenScript May 26, 2025 8:00am Biotech ...

Clinical development phases test new drugs for safety and effectiveness, protecting patients, investors, and trust in medicine.

Edesa Biotech reports financial updates, equity financing for vitiligo drug, and plans for Phase 2 study in 2025.

Absci entered its new drug into Phase I trials in half the time and for many millions of dollars less than it would have cost without AI.

Wed, April 23rd 2025 at 10:15 PM QGAN - bae391fb-78a2-433c-9d20-af445adab0a4.png TOPICS: FDA Animal testing Drug development Human-relevant methods AI models Drug safety Medication costs Clinical ...

WASHINGTON - The US Food and Drug Administration (FDA) said on April 10 it plans to replace animal testing in the development of monoclonal antibody therapies and other drugs with “human ...

The U.S. Food and Drug Administration said on Thursday it plans to replace animal testing in the development of monoclonal antibody therapies and other drugs with "human-relevant methods ...

| Project Optimus is changing the landscape of oncology drug development by redefining dose optimization standards. Learn how sponsors can align with FDA expectations and implement more precise ...

On February 7, Conduit Pharmaceuticals announced that it completed Phase I of its collaboration with Sarborg Limited and is now moving to Phase II, focusing on AI and cybernetics in drug development.

But can AI truly revolutionise drug development and improve success rates? AI in drug development Researchers have applied AI and machine learning to every stage of the drug development process.

Study finds the typical cost of clinical research for developing new drugs is lower than previously estimated, with median costs providing a more accurate reflection than mean costs.

Not developing potency assays and gaining knowledge about MOAs early in the drug development process not only can break ATMP success but can cause costs and delays that lead to company closures.